1. Loftus P. Senate Committee is investigating pricing of hepatitis C drug. Wall Street J July 11, 2014. Available from: http://online.wsj.com/articles/senate-finance-committee-is-investigating-pricing-of-hepatitis-c-drug-1405109206. [Accessed August 11, 2014].
2. The strong financial case for regenerative medicine and the regen industry;Mason;Regen Med,2008
3. The cost of a cure: Medicare’s role in treating hepatitis C;Neuman;Health Affairs Blog,2014
4. Fulton BD, Felton MC, Pareja C, et al. Coverage, cost-control mechanism and financial risk-sharing alternative of high-cost healthcare technologies. 2009. Available from: 〈http://www.cirm.ca.gov/sites/default/files/files/about_cirm/UC-Berkeley%20final%20report%20to%20CIRM%2010.08.09.pdf〉. [Accessed October 18, 2014].
5. Philipson T, von Eschenbach AC. Medical breakthroughs and credit market. Forbes July 9, 2014. Available from: http://www.forbes.com/sites/tomasphilipson/2014/07/09/medical-breakthroughs-and-credit-markets/. [Accessed August 2, 2014].